Lyell Immunopharma, Inc. (LYEL)

Lyell Immunopharma's stock price has been impacted by several events in the past six months. Positive clinical data presentations for LYL314 at the ASH Annual Meeting in December 2025 led to a stock price increase. The acquisition of exclusive global rights to LYL273 in November 2025 strengthened its pipeline. Lyell reported its Q3 2025 financial results in November 2025, showing a net loss of $38.8 million, and announced that its cash position was expected to support its pipeline into 2027. The company initiated a Phase 3 head-to-head CAR T-cell therapy clinical trial (PiNACLE – H2H) in November 2025. CEO Lynn Seely sold 412 shares of common stock in November 2025. Lyell reported Q2 2025 financial results in August 2025, with a net loss of $42.7 million, and highlighted positive clinical data for LYL314 and a $100 million private placement that extended its cash runway into mid-2027.

The demand for Lyell Immunopharma's products and services is not subject to typical consumer demand seasonality. Demand is driven by the ongoing medical need for cancer treatments, the progress and success of its clinical trials, regulatory approvals, and the eventual commercialization of its therapies.

Lyell Immunopharma, Inc. is a clinical-stage cell therapy company focused on developing next-generation T-cell therapies for cancer patients, operating within the Healthcare sector and Biotechnology industry. The company pioneers novel approaches to generate T-cells with potent cancer-killing capabilities designed to deliver long-lasting clinical responses. Its pipeline includes LYL314, a CAR T-cell product in pivotal trials for large B-cell lymphoma, which has received RMAT designation from the FDA. Other product candidates include LYL797 in Phase 1 for solid tumors, LYL845 in Phase 1 targeting multiple solid tumor indications, LYL119, a preclinical ROR1 CAR T-cell product, and LYL273, a GCC-targeted CAR T-cell product for metastatic colorectal cancer, for which Lyell acquired exclusive global rights and has been granted Fast Track designation by the FDA.

Lyell Immunopharma is headquartered in South San Francisco, California, and has facilities in Seattle and Bothell, Washington. The Bothell facility includes the LyFE Manufacturing Center™, which has commercial launch capability and can manufacture over 1,000 CAR T-cell doses per year.

Lyell Immunopharma's brand reputation has been positively influenced by its clinical progress and analyst sentiment. The company has an average brokerage recommendation of 2.25, with two out of four analysts recommending a "Strong Buy," and a "Strong Buy" consensus rating from Public Investing analysts. Positive clinical trial data for LYL314, FDA designations for LYL314 and LYL273, and strategic acquisitions like LYL273 have contributed to its reputation. Concerns noted by analysts include a decrease in research and development expenditure in Q3 2025, potential challenges in penetrating the CAR-T market, and the need for more definitive long-term data on durability and toxicity for LYL273.

Lyell Immunopharma, Inc. has 86 institutional owners and shareholders holding a total of 9,752,080 shares, including major holders such as Arch Venture Corp, MWG Management Ltd., Foresite Capital Management IV, Llc, and Vanguard Group Inc. Individual insiders own approximately 2.35% of the company's shares, with CEO Lynn Seely directly owning 0.11%.